Abstract 565P
Background
The incidence of early-onset colon cancer (early-onset CC, age <50 years (yrs)) is rising with limited data on its clinical and molecular characteristics. We analyzed a real-world cohort of the AIO ColoPredict Plus (CPP) Registry.
Methods
CPP collects data and tissue from patients (pts) with CC UICC stage I-III. Clinical and molecular characteristics were assessed comparing pts <50yrs with pts 50+ using student’s Test and Fishers exact test. Disease-free survival (DFS) rate at 3 yrs was reported. Comorbidity was assessed by Charlson comorbidity index (CCI). Median follow-up was 28.1 months.
Results
Out of 9215 pts 479 (5%) had early-onset CC (median age 44 yrs (22-49) vs. 72 yrs (50-100) in late-onset CC). There were no significant differences regarding sex or BMI. Younger pts had less comorbidities (CCI 0: 91%) than older pts. (CCI 0: 60%, p <0.001). Interestingly, younger patients had larger tumors (p=0.045), more often lymph node metastases (p=0.002) and thus higher UICC stages (p<0,001). Tumor localization was predominantly left-sided in early- (53%) and right-sided in late-onset CC (61%, p<0,001). Younger pts more often received adjuvant chemotherapy (p<0,001) and more frequently oxaliplatin combinations (p<0,001). Mutational analysis was available in 5045 pts, 5% (264 pts) with early-onset CC. No significant difference in K- or N-RAS mutations or MSI were detected. The KRAS subtype p.G12C and BRAF mutations were significantly less prevalent in early-onset compared to late-onset CC (p=0,03 and p<0,01). Younger pts had a better 3 yrs DFS rate.
Conclusions
Pts with early-onset CC in our unique real-world cohort are more often UICC stage III with left primary tumors and better DFS. They also display distinct molecular features which should be considered when making treatment decisions.
Clinical trial identification
DRKS00004305.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Roche, BioNtech.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
601P - Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH
Presenter: Yaqi Wang
Session: Poster session 10
602P - Brazil-TNT: A randomized phase II trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer
Presenter: Diogo Bugano Diniz Gomes
Session: Poster session 10
604P - Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)
Presenter: Miriam Koopman
Session: Poster session 10
605P - First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Presenter: HELENA OLIVERES
Session: Poster session 10
606P - Regional lymph nodes (N+ vs N0) in metastatic colorectal cancer
Presenter: Emerik Osterlund
Session: Poster session 10
608P - Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort
Presenter: René Adam
Session: Poster session 10
609P - The impact of surgical invasiveness on the efficacy of mFOLFOX6 in resected colorectal liver metastasis: An exploratory analysis of JCOG0603
Presenter: Yasuyuki Takamizawa
Session: Poster session 10
610P - Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Presenter: Marinde Bond
Session: Poster session 10
611P - SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
Presenter: Rui-Hua Xu
Session: Poster session 10